Core Insights - In 2024, the company achieved operating revenue of 1.142 billion yuan, representing a year-on-year growth of 9.94% [1] - The net profit attributable to shareholders was 148 million yuan, with a non-recurring net profit of 125 million yuan [1] Business Segments - The non-clinical CRO business generated revenue of 1.089 billion yuan, an increase of 8.99% year-on-year, with safety services contributing 959 million yuan, up 7.86% [1] - The clinical CRO business reported operating revenue of 46.9385 million yuan, reflecting a significant growth of 27.17% [1] New Orders and Market Position - In 2024, the company signed new orders amounting to 819 million yuan, with a backlog of 973 million yuan by the end of the year [1] - The number of new orders for new drug clinical trial applications and new drug marketing applications combined saw a year-on-year increase of 18.37% [1] Technological Advancements - The company has developed several core technology platforms, including toxicity biomarker evaluation and non-clinical safety evaluation systems, contributing to nearly 200 innovative drug research services [2] - The company is actively enhancing its "AI+" capabilities, focusing on the integration of artificial intelligence with industry scenarios, and exploring deep learning-based intelligent pathology diagnostic systems [2]
益诺思发布上市后首份年报：2024年营收达11.42亿元 归母净利润为1.48亿元